Halozyme Therapeutics Inc (HALO)

[maumar]

Blockbuster potential for Datarumumab.

"According to a recent update, the Genmab’s Datarumumab has yielded very positive results, which are even comparable in performance to Pharmacokinetics of Intravenous injections. The results have put Revlimid in some very serious trouble as the analyst believes that the other drug is better in almost all three areas, namely efficacy, safety and convenience. The challenges faced by Celgene in the long term are now very harsh and the company needs to come up with a proper strategy to counter the headwinds.

The results show that Datarumumab might lead to reduction of infusion time by around 30 minutes. Combining that with the ease of subcutaneous dosage route and better efficiency makes for a very strong case against the competition. The drug might just end up replacing Revlimid as the central part of therapy for similar diseases, speculated the analyst."

http://www.thecountrycaller.com/61814-daratumumab-poses-threat-to-celgene-corporations-celg-revlimid-bmo-capital/